ID   HOC-21
AC   CVCL_8692
SY   Human Ovarian Cancer-21
DR   ChEMBL-Cells; CHEMBL3308669
DR   ChEMBL-Targets; CHEMBL614829
DR   Cosmic; 877479
DR   Cosmic; 1152559
DR   PubChem_Cell_line; CVCL_8692
DR   Wikidata; Q54890104
RX   PubMed=4436993;
RX   PubMed=6163305;
RX   PubMed=6174649;
CC   Population: Japanese.
CC   Doubling time: 28 hours (PubMed=4436993).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7700; Ovarian adenocarcinoma
DI   ORDO; Orphanet_213504; Adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 14
//
RX   PubMed=4436993; DOI=10.2302/kjm.23.53;
RA   Yamada T.;
RT   "The cellular biology of a newly established cell line of human
RT   ovarian adenocarcinoma in vitro.";
RL   Keio J. Med. 23:53-70(1974).
//
RX   PubMed=6163305;
RA   Sekiya S., Takamizawa H.;
RT   "Effect of anticancer drugs on in vitro survival of cell lines derived
RT   from various gynecologic tumors.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 33:373-376(1981).
//
RX   PubMed=6174649;
RA   Sekiya S., Kawata M., Inaba N., Takamizawa H.;
RT   "Studies on marker substances in cell lines derived from various human
RT   gynecologic tumors.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 34:37-42(1982).
//